List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 45 studies with search of: bexxar lymphoma
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Diffuse Large Cell Lymphoma
Intervention: Drug: Iodine I 131 Tositumomab Therapeutic Regimen
2 Recruiting Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Disease
Intervention: Drug: I-131 Tositumomab therapeutic regimen
3 Terminated A Comparison Of Rituximab vs. Iodine I 131 Tositumomab Therapeutic Regimen (i.e., BEXXAR®) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Iodine I 131 Tositumomab Therapeutic Regimen;   Drug: Rituximab
4 Active, not recruiting Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)
5 Active, not recruiting Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)
Conditions: Lymphoma, B-Cell;   Lymphoma, Large-Cell, Immunoblastic;   Lymphoma, Non-Hodgkin
Interventions: Drug: Autologous transplantation using rituxan/BEAM;   Drug: Autologous transplantation using Bexxar/BEAM
6 Recruiting Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant
Conditions: B-Cell Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Drug: Bexxar
7 Recruiting Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
Conditions: Non-Hodgkin's Lymphoma;   Follicular Lymphoma
Interventions: Drug: Iodine I -01 Tositumomab (Bexxar);   Procedure: External Beam Radiation Therapy
8 No longer available Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Biological: Iodine I 131 Tositumomab Therapeutic Regimen
9 Active, not recruiting Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab
Condition: Non-Hodgkin's Lymphoma
Intervention: Biological: Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)
10 Completed Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine I 131 Tositumomab
11 Active, not recruiting Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-Cell
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab followed by CHOP
12 Active, not recruiting Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine-131 Anti-B1 Antibody
13 Completed Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Iodine-131 Anti-B1 Antibody;   Drug: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
14 Withdrawn A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
Conditions: Lymphoma, Small Cleaved-Cell, Follicular;   Lymphoma, Large-Cell, Follicular;   Lymphoma, Follicular;   Lymphoma, Non-Hodgkin
Interventions: Drug: Ibritumomab Tiuxetan;   Drug: Iodine I 131 Tositumomab
15 Active, not recruiting Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: dose-escalation
16 Completed A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: Bortezomib and Tositumomab I-131
17 Active, not recruiting Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine-131 Anti-B1 Antibody
18 Recruiting Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Tositumomab and iodine I 131 tositumomab;   Procedure: External beam radiotherapy
19 Completed Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab
20 Recruiting Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Large-Cell, Diffuse
Intervention: Drug: Tositumomab and iodine I 131 tositumomab

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services